<DOC>
	<DOCNO>NCT01630369</DOCNO>
	<brief_summary>Primary Objective : - To evaluate decrease Hb A1c â‰¥ 1 % 6 month treatment patient Type 2 Diabetes Mellitus ( T2DM ) uncontrolled Oral Antidiabetics ( OADs ) Secondary Objectives : - To evaluate percentage patient Hb A1c &lt; 7.5 % , - To evaluate rate hypoglycaemia ( symptomatic , severe ) - To evaluate middle dose insulin per product - Insuman Basal , Insuman Comb , Insuman Rapid 6 month treatment - To evaluate change Fasting Plasma Glucose ( FPG ) 6 month treatment - To assess overall safety - To evaluate efficacy education course Diabetes Schools ( % correct answer second test compare test initial level )</brief_summary>
	<brief_title>Efficacy Safety Insuman Basal/Comb/Rapid Patients With Type 2 Diabetes</brief_title>
	<detailed_description>6 month</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion criterion : T2DM patient uncontrolled maximum tolerate dose 12 OADs Males Female &gt; 18 year HbA1c &gt; 7.5 % Patients abilities selfmonitoring Diabetes , manage patient 's diary , ability obtain education Diabetes School , completion Questionnaire It expect patient remain stable dose OADs within 6 month treatment Exclusion criterion : Type 1 diabetes Current temporary insulin therapy ( gestational diabetes , pancreas cancer , surgery , clinical trial ) Any clinically significant acute major organ systemic disease make interpretation evaluation result difficult Patient planning pregnancy next 6 month The patient participate another clinical study last 28 day prior Visit 1 The patient drug user ( currently past ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>